Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Leaders Speculate On FTC Vs. Amgen/Horizon Fallout

Executive Summary

Pfizer chief clinical officer William Pao, Roche pharma CEO Teresa Graham and others weighed in on what FTC’s action could mean for pharma M&A at the Financial Times Pharma Summit.

You may also be interested in...

Reading The FTC Tea Leaves: Investors Await Insights For M&A

Pfizer and Amgen both have large M&A deals under regulatory review, and investors will be eager to hear updates on how those transactions are progressing during Q2 reporting.

Biopharma M&A’s Busy Pace Expected To Continue During 2023’s Second Half

Analysts from PwC see multiple factors that should continue to drive bolt-on deals valued at $1bn or more, but heightened FTC scrutiny of large M&A may discourage bigger transactions.

Regeneron CEO Takes Industry Counterview On FTC News: “I’m Glad They’re Looking Into This”

Leonard Schleifer said it is time for US regulators to review whether certain rebate practices are anti-competitive, while speaking at the Financial Times US Pharma & Biotech Summit.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts